InSightec ExAblate cancer pain therapy:
This article was originally published in Clinica
Executive Summary
InSightec can now expand the use of its magnetic resonance-guided focused ultrasound (MRgFUS) therapy from treatment of uterine fibroids to pain palliation of bone metastases. Its product, called ExAblate 2000, can alleviate pain, has the potential to lower reliance on analgesics and can provide patients with the opportunity for improved quality of life, the company said of the new indication. It is estimated that 100,000 people in Europe are diagnosed with bone metastases every year, said the Haifa, Israel-based firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.